GLOW

NCT03653507 📎

Regimen

Experimental
zolbetuximab + CAPOX
Control
placebo + CAPOX

Population

CLDN18.2-positive HER2-negative advanced gastric/GEJ cancer as first-line therapy

Key finding

mPFS 8.21 vs 6.80 mo (HR 0.687, 95% CI 0.544-0.866, p=0.0007); mOS 14.39 vs 12.16 mo (HR 0.771, 95% CI 0.615-0.965, p=0.0118)

Source: PMID 37524953

Timeline

    Guideline citations

    • NCCN GASTRIC (p.30)
    • CSCO GASTRIC 2025 (p.31)⚠️ OCR source